3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Rectal Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Colorectal Neoplasms
2
Barrett Esophagus
2
Adenocarcinoma Of Esophagus
2
Urogenital Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Colitis
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Endoscopy
×
90 days
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled